^
    1d
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Feb 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    2d
    EAY131-S2: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    Mekinist (trametinib)
    2d
    EAY131-S1: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Mekinist (trametinib)
    3d
    Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    RAS mutation
    |
    Erbitux (cetuximab) • Kolupin (tunlametinib) • TheraCIM (nimotuzumab)
    3d
    RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma (clinicaltrials.gov)
    P4, N=110, Recruiting, Fudan University
    New P4 trial • Real-world evidence
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Kolupin (tunlametinib)
    4d
    Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma (clinicaltrials.gov)
    P1, N=50, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    |
    BRAF V600
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    4d
    STARBOARD: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P3, N=257, Active, not recruiting, Pfizer | Trial completion date: Mar 2026 --> Aug 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    5d
    Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. (PubMed, iScience)
    In KRAS-mutant cancer models, trametinib treatment caused dysregulation of the purine biosynthetic pathway driven by reductions in enzyme GART. This induced vulnerability nominated purine analog 6-thioguanine as a synergistic partner...In vivo, the treatment significantly increases overall survival without systemic toxicity. Integrating drug-induced multi-omic changes with functional screening identifies therapeutic strategies, supporting the use of purine analogs with MEK inhibitors for KRAS-mutant tumors.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • thioguanine
    7d
    Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: The BEETS (JACCRO CC‑18) study. (PubMed, Oncologist)
    In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.
    Journal • Real-world evidence
    |
    BRAF (B-raf proto-oncogene) • CRP (C-reactive protein)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    7d
    Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. (PubMed, Oncologist)
    The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    7d
    Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov)
    P1, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Zykadia (ceritinib)
    7d
    DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. (clinicaltrials.gov)
    P2/3, N=30, Not yet recruiting, Cancer Research UK
    New P2/3 trial
    |
    BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)